MedTrace Logo

n-3 PUFA for Vascular Cognitive Aging

NCT01953705 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2020-09-04

No results posted yet for this study

Summary

Brain scans can help identify changes that appear to increase risk for cognitive decline and dementia. Some of these brain changes are thought to reflect actual damage to the small blood vessels that support normal brain function. This clinical trial will determine whether an omega 3 polyunsaturated fatty acid (PUFA) therapy can promote brain health by supporting the small blood vessels in the brain over 3 years in older adults at high risk for cognitive decline and dementia of Alzheimer's type.

Conditions

  • Age Related Cognitive Decline
  • Alzheimer's Disease
  • Vascular Dementia
  • Endothelial Dysfunction
  • Executive Dysfunction

Interventions

DRUG

Omega 3 PUFA

fish oil concentrate standardized to long chain n-3 PUFA content

DRUG

Placebo

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Gene Bowman, ND, MPH · Oregon Health and Science University

  • Lynne Shinto, ND, MPH · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01953705 on ClinicalTrials.gov